Literature DB >> 20053442

The performance of photooxidatively crosslinked acellular bovine jugular vein conduits in the reconstruction of connections between pulmonary arteries and right ventricles.

Wei-Dong Lü1, Ming Zhang, Zhong-Shi Wu, Tie-Hui Hu, Zhao-Jun Xu, Wei Liu, Ye-Rong Hu.   

Abstract

In this study, valved photooxidatively crosslinked acellular bovine jugular vein conduits (BJVCs) were implanted in young dogs to reconstruct the connections of pulmonary arteries and right ventricles, with acellular conduits used as controls. All acellular conduits had moderate to severe valvular dysfunction and were explanted at 1-month implantation (n = 5). Histological examination showed inflammatory cell infiltration and intimal hyperplasia in the walls, and severe inflammatory cell infiltration and thrombosis in the valves. The photooxidatively crosslinked acellular conduits were retrieved at 1-month (n = 5) and 6-month (n = 5) implantations respectively. These conduits had excellent valvular function at retrieval. Their walls and valves were still soft and smooth without calcification and hemangioma. Endothelialization in valves and luminal walls was unsatisfied at 1-month retrieval, and was improved at 6-month retrieval. Host cells infiltrated and migrated from outer layer to the middle layer, with tissue remolding and regeneration found in these recellular regions. Histological examination and tissue content assay demonstrated that degeneration and regeneration of collagens and glycosaminoglycans were comparable, but elastic fibers gradually degraded. Photooxidatively crosslinked acellular BJVCs resist calcification and thrombosis and have regeneration patterns, with excellent hemodynamic performance. 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20053442     DOI: 10.1016/j.biomaterials.2009.12.046

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  7 in total

1.  Controlled release of chitosan/heparin nanoparticle-delivered VEGF enhances regeneration of decellularized tissue-engineered scaffolds.

Authors:  Qi Tan; Hao Tang; Jianguo Hu; Yerong Hu; Xinmin Zhou; Yunming Tao; Zhongshi Wu
Journal:  Int J Nanomedicine       Date:  2011-05-02

2.  Effect of naturally derived surgical hemostatic materials on the proliferation of A549 human lung adenocarcinoma cells.

Authors:  Wei-Dong Lü; Yi-Zhi Liu; Yan-Qi Yang; Zhi-Gang Liu; Kun Zhao; Jian-Rong Lu; Guang-Yan Lei; Yi-Yu Wang; Lin Cai; Rui-Fang Sun
Journal:  Mater Today Bio       Date:  2022-03-04

3.  Photooxidation and Pentagalloyl Glucose Cross-Linking Improves the Performance of Decellularized Small-Diameter Vascular Xenograft In Vivo.

Authors:  Yuhong Liu; Chunyang Chen; Xinlong Xie; Haoyong Yuan; Zhenjie Tang; Tao Qian; Yalin Liu; Mingzhe Song; Sixi Liu; Ting Lu; Zhongshi Wu
Journal:  Front Bioeng Biotechnol       Date:  2022-03-24

4.  Decellularized bovine jugular vein and hand-sewn ePTFE valved conduit for right ventricular outflow tract reconstruction in children undergoing Ross procedure.

Authors:  Haoyong Yuan; Ting Lu; Zhongshi Wu; Yifeng Yang; Jinlan Chen; Qin Wu; Sijie Wu; Hong Zhang; Tao Qian; Can Huang
Journal:  Front Cardiovasc Med       Date:  2022-09-07

5.  Heparin nanomodification improves biocompatibility and biomechanical stability of decellularized vascular scaffolds.

Authors:  Yunming Tao; Tiehui Hu; Zhongshi Wu; Hao Tang; Yerong Hu; Qi Tan; Chunlin Wu
Journal:  Int J Nanomedicine       Date:  2012-11-26

6.  The application of pulmonary valve biorifice for reconstruction of right ventricular outflow tract in tetralogy of Fallot.

Authors:  Jinfu Yang; Wenwu Zhou; Li Xie; Lian Xiong; Xin Wang; Yifeng Yang
Journal:  J Cardiothorac Surg       Date:  2013-06-11       Impact factor: 1.637

7.  Development of an acellular tumor extracellular matrix as a three-dimensional scaffold for tumor engineering.

Authors:  Wei-Dong Lü; Lei Zhang; Chun-Lin Wu; Zhi-Gang Liu; Guang-Yan Lei; Jia Liu; Wei Gao; Ye-Rong Hu
Journal:  PLoS One       Date:  2014-07-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.